Compositions and methods for treating retinal degradation
View Patent ↗The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
1. A method for treating retinal degeneration, comprising:
administering an effective amount of a composition to a subject in need of treatment for retinal degeneration,
wherein the composition comprises a reverse transcriptase inhibitor selected from:
(i) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) lamivudine (3TC);
(v) cordycepin;
(vi) azidothymidine (AZT);
(vii) abacavir (ABC); and
(viii) a combination thereof.
2. The method of claim 1 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.
3. The method of claim 2 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.
4. The method of claim 1 , comprising reducing ATP-induced permeability of a cell.
5. The method of claim 4 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.
6. The method of claim 1 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.
7. The method of claim 1 , comprising inhibiting activation of at least one inflammasome in a subject's eye.
8. The method of claim 7 , wherein the at least one inflammasome is selected from an NLRP3 inflammasome, an IL-1 beta inflammasome, and a combination thereof.
9. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
10. A compound having the structure
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.
12. A compound having the structure
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.
14. A method for treating retinal degeneration, comprising:
administering an effective amount of a composition to a subject in need of treatment for retinal degeneration,
wherein the composition comprises:
(i) a compound having the structure of
or a pharmaceutically acceptable salt thereof; or
(ii) a compound having the structure of
or a pharmaceutically acceptable salt thereof.
15. The method of claim 14 , wherein the composition further comprises: stavudine (d4T), lamivudine (3TC), cordycepin, azidothymidine (AZT), abacavir (ABC), or a combination thereof.
16. The method of claim 14 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.
17. The method of claim 16 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.
18. The method of claim 14 , comprising reducing ATP-induced permeability of a cell.
19. The method of claim 18 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.
20. The method of claim 14 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.
21. The method of claim 14 , comprising inhibiting activation of at least one inflammasome in a subject's eye.
22. The method of claim 21 , wherein the at least one inflammasome is selected from an NLRP3 inflammasome, an IL-1 beta inflammasome, and a combination thereof.
23. The method of claim 14 , wherein the composition comprises a pharmaceutically acceptable carrier.